Rain Therapeutics
8000 Jarvis Ave Suite 204
Newark
CA
94560
United States
Tel: 510-953-5559
Website: https://rainthera.com/
Email: info@rainthera.com
About Rain Therapeutics
Rain was founded with a focus on developing therapies that effectively target genetically-driven cancers to help patients live life to the fullest. Leveraging both an acquisition-based business model and internal research, we aim to become a leading precision oncology company that develops and commercializes small molecule therapies.
Our vision is to help cancer patients live life to the fullest.
Our uncompromised dream is to mobilize the best precision oncology therapies for patients suffering from cancer. We are rooted in this purpose – extending the quality and length of life for cancer patients where we may be their best hope.
Stock Symbol: RAIN
32 articles with Rain Therapeutics
-
UPDATE -- Rain Therapeutics Announces Completion of Enrollment in Phase 3 MANTRA Trial for Milademetan in Liposarcoma
8/4/2022
Rain Therapeutics Inc. announced completion of enrollment in its Phase 3 MANTRA randomized, global, registrational trial of its lead product candidate, milademetan, an oral, small molecule inhibitor of the MDM2-p53 complex that reactivates p53.
-
Rain Therapeutics Reports Second Quarter 2022 Financial Results and Highlights Recent Progress
8/4/2022
Rain Therapeutics Inc., a late-stage biotechnology company developing precision oncology therapeutics with a lead product candidate, milademetan, an oral, small molecule inhibitor of the MDM2-p53 complex that reactivates p53, reported financial results for the second quarter and six months ended June 30, 2022, along with an update on the Company’s key developments, business operations and upcoming milestones.
-
Rain Therapeutics Announces Completion of Enrollment in Phase 3 MANTRA Trial for Milademetan in Liposarcoma
8/4/2022
Rain Therapeutics Inc. (NasdaqGS: RAIN), (Rain), a late-stage biotechnology company developing precision oncology therapeutics, today announced completion of enrollment in its Phase 3 MANTRA randomized, global, registrational trial of its lead product candidate, milademetan, an oral, small molecule inhibitor of the MDM2-p53 complex that reactivates p53.
-
BioSpace spoke with three CEOs: Alto Neuroscience’s Dr. Amit Etkin, Omega Therapeutics’ Mahesh Karande and Rain Therapeutics’ Avanish Vellanki about their companies' employment growth.
-
In the coming 12 months, Rain expects to have an interim readout for a Phase II study of its liposarcoma therapy, milademetan, and a pivotal readout for its Phase III trial of the same compound.
-
Rain Therapeutics Reports First Quarter 2022 Financial Results and Highlights Recent Progress
5/4/2022
Rain Therapeutics Inc. reports financial results for the first quarter ended March 31, 2022, along with an update on the Company's key developments, business operations and upcoming milestones.
-
Kenneth Frazier, executive chairman and former chief executive officer of Merck, joins former colleagues Roger Perlmutter and Roy Baynes at the well-financed company.
-
Rain Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Highlights Recent Progress
3/3/2022
Rain Therapeutics Inc. (NasdaqGS: RAIN), (Rain), a late-stage company developing precision oncology therapeutics, today reports financial results for the fourth quarter and full year ended December 31, 2021, along with an update on the Company's key developments, business operations and upcoming milestones.
-
BioSpace Movers & Shakers, Feb. 11
2/11/2022
Well into the new year, biopharma and life sciences companies bolster their executive leadership teams and boards with these Movers & Shakers. -
CEO to CEO: Tips for First-time Founders
1/11/2022
BioSpace picked the brains of 10 biotech CEOs and founders, to solicit their advice for first-time founders. -
Clinical Catch-Up: November 15-19
11/22/2021
With the last full week before the Thanksgiving week in the U.S., companies had a fair amount of clinical trial news. Here’s a look. -
Rain Therapeutics Doses First Patient in Phase 2 Basket Trial of Milademetan for MDM2-Amplified Advanced Solid Tumors (MANTRA-2)
11/19/2021
Rain Therapeutics Inc., a late-stage company developing precision oncology therapeutics, announced that the first patient has been dosed in the multicenter, single arm, open-label, Phase 2 basket trial evaluating milademetan, an oral mouse double minute 2 inhibitor, for the treatment of MDM2-amplified advanced solid tumors.
-
Clinical Catch-Up: November 8-12
11/15/2021
It was another busy week for clinical trial news. Here’s a look. -
Rain Therapeutics Reports Third Quarter 2021 Financial Results and Highlights Recent Progress
11/10/2021
Rain Therapeutics Inc. (NasdaqGS: RAIN), (Rain), a late-stage company developing precision oncology therapeutics, today reports financial results for the third quarter and nine months ended September 30, 2021, along with an update on the company's key developments, business operations and upcoming milestones.
-
Rain Therapeutics Plans Phase 2 Merkel Cell Carcinoma Clinical Trial (MANTRA-3) of Milademetan
11/9/2021
Rain Therapeutics Inc. today announced its plan to commence a Phase 2 linical trial, named MANTRA-3, evaluating the efficacy of milademetan, an oral mouse double minute 2 (MDM2) inhibitor, as a monotherapy for the treatment of patients with Merkel cell carcinoma (MCC) refractory to immune checkpoint inhibition (ICI) in mid-2022.
-
Rain Therapeutics to Report Third Quarter 2021 Financial Results and Highlights of Recent Progress on November 10, 2021
11/3/2021
Rain Therapeutics Inc. today announced it will report financial results for the third quarter that ended September 30, 2021 and highlights of recent progress, on Wednesday, November 10, 2021.
-
Rain Therapeutics Hosting Research and Development (R&D) DayTuesday, November 9th at 11:00 am ET
10/25/2021
Rain Therapeutics Inc., (NasdaqGS: RAIN), (“Rain”), a late-stage company developing precision oncology therapeutics, today announced that it will host a virtual Research and Development (R&D) day on Tuesday, November 9, 2021 from 11:00 am to 2:00 pm Eastern Time.
-
Rain Therapeutics Presents Data on Milademetan (RAIN-32) at the 2021 AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics
10/7/2021
Rain Therapeutics Inc.,, a late-stage company developing precision oncology therapeutics, announced data on its oral mouse double minute 2 inhibitor, milademetan, presented at the 2021 AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics held virtually October 7-10, 2021.
-
Rain Therapeutics to Present on Milademetan at the 2021 AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics
10/4/2021
Rain Therapeutics Inc. today announced it will be presenting three posters highlighting its oral mouse double minute 2 (MDM2) inhibitor, milademetan, and the importance of MDM2 as a therapeutic target at the 2021 AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics
-
Rain Therapeutics to Present at the Cantor Fitzgerald Virtual Global Healthcare Conference
9/22/2021
Rain Therapeutics Inc., a late-stage company developing precision oncology therapeutics, announced that Avanish Vellanki, co-founder, chairman and chief executive officer of Rain, will present at the Cantor Fitzgerald Virtual Global Healthcare Conference being held virtually September 27-30, 2021.